BARDA Stakeholder Portal
HHS Icon U.S. Department of Health & Human Services
  Administration for Strategic Preparedness and Response
US Flag An official website of the United States government Here’s how you know
×
Shield

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Lock

Secure .gov websites use HTTPS

A lock or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites

BARDA Programs

Our strategic priorities

Newsroom

Get the latest

Partner with Us

Learn about BARDA's funding opportunities

ACTIVE OPPORTUNITY SPOTLIGHT

2026 Rapid Response Partnership Vehicle (RRPV) General Membership Meeting

Register now for the 2026 RRPV General Membership Meeting, which will be held on August 26-27, 2026, in Arlington, VA. The Meeting brings together government, industry, and academic stakeholders to exchange insights, discuss priorities and requirements, create and strengthen collaborations and partnerships, support market research, and advance countermeasure development.

REGISTER TODAY
Speakers on stage and attendees

ReadyDetect: Blood Sampling Competition

Concept Stage

$5 million competition to advance next-generation capillary blood self-collection and processing devices for point-of-need diagnostics. ReadyDetect seeks solutions for sample collection that can support diagnostic testing across BARDA priority pathogens and enable low-cost, scalable, CLIA-waivable use in both pediatric and adult populations. Apply by August 7, 2026.

APPLY TODAY
hands using blood collection device

$80+M Single Shield Prize Competition for Vaccine Innovation

The Single Shield Prize, administered by Luminary Labs, is an $80+ million, multi-stage competition to advance single-administration vaccine platforms for pandemic influenza A(H5N1). The competition seeks innovative solutions that enable development of recombinant hemagglutinin protein or inactivated virus vaccines that provide protection in a single visit. Apply by January 15, 2027.

APPLY TODAY
provider and patient in care setting
BARDA Seal

BARDA Programs

Chemical, Biological, Radiological & Nuclear
(CBRN)

CBRN helps innovators develop promising MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval.

CBRN Programs
  • Antimicrobials
  • Antivirals & Antitoxins
  • Burn & Blast MCMs
  • Chemical MCMs
  • Radiological & Nuclear MCMs
  • Vaccines
Learn More
Clinical Development
(DCD)

Providing expert knowledge and support to BARDA’s programs in advanced product development and clinical research, including supporting BARDA clinical studies via the Clinical Studies Network (CSN). Integrated centralized resource: Our focus is BARDA’s success.

Learn More
Contract Management and Acquisition
(CMA)

CMA provides flexible and innovative acquisition solutions in support of BARDA’s mission. CMA strives to enhance the U.S. government’s contracting capabilities to respond quickly to both known and emerging public health threats.

Learn More
Detection, Diagnostics, and Devices Infrastructure
(DDDI)

DDDI invests in diagnostics and devices across the spectrum of advanced research and development, stockpiling, and domestic manufacturing capacity expansion.

Learn More
Nonclinical Development
(DNCD)

DNCD provides nonclinical models, tools, and expertise to advance MCM development. DNCD provides expertise and laboratory capacity to establish and share nonclinical models, conduct appropriate nonclinical studies to support FDA approval, and evaluate potential MCM candidates prior to BARDA investment.

Learn More
Research, Innovation & Ventures
(DRIVe)

DRIVe works to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. DRIVe aims to de-risk the most promising technologies and capabilities.

DRIVe Programs
  • DRIVe’s R&D Programs
  • Ecosystem Programs
Learn More
Influenza & Emerging Infectious Diseases
(IEID)

Influenza & EID invests in advanced research and development, manufacturing capacity, and procurement of MCMs to protect the nation from pandemic influenza and other emerging infectious diseases.

Influenza & EID Programs
  • Pandemic Vaccines and Adjuvants
  • Therapeutics
  • Vaccines Development
Learn More
Pharmaceutical Countermeasures and Infrastructure
(PCI)

PCI provides expertise to strengthen the nation’s ability to manufacture, distribute, administer, and scale production of lifesaving MCMs.

Learn More
Regulatory & Quality Affairs
(RQA)

RQA ensures that BARDA-supported MCMs are safe, effective, and in compliance with relevant and current laws, regulations, and guidelines by providing technical expertise and innovative regulatory and policy approaches.

RQA Programs
  • Regulatory Affairs
  • Quality Affairs
  • Regulatory Operations
Learn More

Special Initiatives and Other Programs

BARDA invests in innovative projects across our portfolio, including promising technologies, platforms, and programs. We launch and support efforts designed to accelerate and foster smaller new projects.

Project NextGen

Radiation Emergency Medical Management (REMM)

PRISM: Primary Response Incident Scene Management

Chemical Hazard Emergency Medical Management (CHEMM)